To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

Phase 1 Completed 42 enrolled Humanis

RandomizedCrossoverOpen-labelOther

Summary

An open label, balanced, randomized single-dose, two-treatment, two sequence, four-period, Full Replicate, crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.

Timeline

Start: 2025-04-30
Primary completion: 2025-06-16
Completion: 2025-06-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bilastine	Small molecule	20 mg	Oral

To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

Summary

Timeline

Drugs

Indications